Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer
转移性疾病体积和转移性疾病出现时间对接受恩扎卢胺或醋酸阿比特龙联合泼尼松一线治疗的转移性去势抵抗性前列腺癌患者的临床影响
期刊:Journal of Translational Medicine
影响因子:7.5
doi:10.1186/s12967-022-03861-2
Nuzzo, Pier Vitale; Pederzoli, Filippo; Saieva, Calogero; Zanardi, Elisa; Fotia, Giuseppe; Malgeri, Andrea; Rossetti, Sabrina; Valenca Bueno, Loana; Andrade, Livia Maria Q S; Patrikidou, Anna; Mestre, Ricardo Pereira; Modesti, Mikol; Pignata, Sandro; Procopio, Giuseppe; Fornarini, Giuseppe; De Giorgi, Ugo; Russo, Antonio; Francini, Edoardo
